A randomized, open-label, active controlled, parallel group, multicenter phase 3 study to evaluate the efficacy and tolerability of Bamlanivimab and Etesevimab, Casirivimab and Imdevimab, and Sotrovimab versus Standard of Care in patients with mild to moderate COVID-19 disease (AntiCov) A randomized, open-label, active controlled, parallel group, multicenter phase 3 study to evaluate the efficacy and tolerability of Bamlanivimab and Etesevimab, Casirivimab and Imdevimab, and Sotrovimab versus Standard of Care in patients with mild to moderate COVID-19 disease (AntiCov)
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Bamlanivimab (Primary) ; Casirivimab (Primary) ; Etesevimab (Primary) ; Imdevimab (Primary) ; Sotrovimab (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms AntiCov
- 20 Feb 2022 Planned End Date changed to 17 Jul 2022.
- 20 Feb 2022 Status changed from not stated to recruiting.
- 03 Sep 2021 New trial record